Cardiology – Clinical Trial Results

Robin Nijveldt and C. Michael Gibson Discuss: iMODERN:iFR- vs. Cardiac MRI-Guided Revascularization of Non-Culprit Lesions in STEMI

October 28, 2025

Disclosures: TBD

Ruben de Winter and C. Michael Gibson Discuss: PROCTOR:Native Vessel vs. SVG PCI in Patients With Prior CABG

October 28, 2025

Disclosures: TBD

Matthias Bossard and C. Michael Gibson Discuss: VICTORY:Intravascular Lithotripsy vs. Super-High-Pressure PTCA in Calcified and Refractory Coronary Lesions

October 26, 2025

Disclosures: TBD

Christian M. Spaulding and C. Michael Gibson Discuss: SELUTION DeNovo: Sirolimus-Eluting DCB vs. DES in De Novo Coronary Lesions

October 26, 2025

Disclosures: TBD

Dr. Hofmann and Dr. Gibson discuss HELP-MI SWEDEHEART trial

September 5, 2025

Disclosures: TBD

#ACC2025 Antithrmbotic / Antiplatelet Wrap Up:

April 11, 2025

Dr. Bhatt and I discuss ticagrelor reversal using bentracimab from the REVERSE-IT trial, as well as comparable efficacy and safety […]

Dr. Xiaojie Xie and Dr. C. Michael Gibson discuss: Efficacy And Safety Of SHR-1918, An Angiopoietin-like 3 Monoclonal Antibody, In Combination With Lipid-lowering Therapy In Patients With Suboptimally Controlled Hyperlipidemia: A Multicenter, Randomized, Double Blind, Placebo-controlled Phase 2 Trial

March 31, 2025

Disclosures: TBD

Dr. Michael J. Koren and Dr. C Michael Gibson discuss: Efficacy And Safety Of Azd0780, An Oral Small Molecule Pcsk9 Inhibitor For Treatment Of Hypercholesterolemia: Results From A Ph2b Randomized Placebo-controlled Clinical Trial

March 31, 2025

Disclosures: TBD

Dr. Marco G. Mennuni and Dr. C. Michael Gibson discuss: Alternative Antithrombotic Pathways In Acute Myocardial Infarction With Large Thrombus Burden: A Randomized Trial ARISE-ARMYDA 7

March 31, 2025

Disclosures: TBD

Dr. Jian-An Wang and I discuss: Comparison Of Angiography-derived Fractional Flow Reserve-guided And Intravascular Ultrasound-guided Percutaneous Coronary Intervention Strategies: The FLAVOUR II Trial

March 31, 2025

Disclosures: TBD